Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

The population is aging at a rate never seen before in human history. As the number of
elderly adults grows, it is imperative we expand our understanding of the underpinnings of …

Predicting the clinical response to chemotherapeutic or targeted treatment in patients with
locally advanced or metastatic lung cancer requires an accurate and affordable tool. Tumor …

Summary We analyzed 2,532 lung adenocarcinomas (LUAD) to identify the
clinicopathological and genomic features associated with metastasis, metastatic burden …

Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

Introduction Access to targeted therapies for lung cancer depends on the accurate
identification of patients' biomarkers through molecular testing. The International Association …

Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a
subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling …

Molecular characterization of non-small cell lung cancer (NSCLC) marked an historical
turning point for the treatment of lung tumors harboring kinase alterations suitable for …

Summary Background The US Preventive Services Task Force (USPSTF) recommends lung
cancer screening among individuals aged 55–80 years with a 30 pack-year cigarette …